Episode 4: Achalasia Treatment — Decision Tree and Landmark TrialsEpisode keywords: achalasia treatment, POEM procedure, Heller myotomy, pneumatic dilation achalasia, botulinum toxin achalasia, Boeckxstaens trial NEJM, Werner trial NEJM, Nissen fundoplication achalasia, achalasia GERD after POEM, blown-out myotomyEpisode SummaryEvery achalasia treatment has one goal: reduce LES resting pressure so it no longer obstructs ingested material. No treatment restores peristalsis. All are palliative. This episode covers the treatment hierarchy from pharmacotherapy to POEM, the three landmark RCTs that define the evidence base, and the current ACG and ASGE guideline recommendations — including which treatment is preferred for Type III achalasia.Key TopicsThree anchoring principles:All treatments target LES pressure reduction — not esophageal body function.No treatment restores peristalsis. Lost ganglion cells do not return.All therapies deteriorate over time. Patients should anticipate retreatment.Pharmacotherapy (nitrates/calcium channel blockers): Smooth muscle relaxants taken sublingually 10–30 minutes pre-meal. Side effects common. ACG indicates use only when patient cannot undergo definitive therapy AND has failed botulinum toxin. Last resort, not first line.Botulinum toxin injection: Endoscopic injection into LES. Blocks excitatory cholinergic neurons. Remission in ~67% at 6 months. Not durable — most need repeat injections; only ~67% of initial responders maintain remission at one year with repeated injections. Submucosal fibrosis from repeated injections complicates subsequent myotomy. Not a definitive therapy. Use in elderly/infirm patients who cannot tolerate definitive procedures.Pneumatic dilation (PD): 30–40 mm balloons tear LES muscle fibers. Good-to-excellent response in 60–85% after a single session. ~50% require additional therapy within 5 years. Perforation rate 2–5%. Reflux esophagitis in ~5%.Laparoscopic Heller myotomy (LHM): Surgical division of LES muscle under direct visualization. Always paired with partial fundoplication — Dor (anterior) or Toupet (posterior). Nissen (360°) fundoplication is avoided — the aperistaltic esophagus cannot push through a complete wrap. Good-to-excellent response 70–90%. 85% sustained remission at 10 years, 65% at 20 years. Reflux esophagitis ~10%.POEM (per-oral endoscopic myotomy): Submucosal tunnel approach, myotomy performed from inside. Meta-analysis of 2,373 patients: 98% short-term success. Advantage: proximal extension of myotomy for Type III. Disadvantage: no antireflux procedure — GERD symptoms 8.5%, reflux esophagitis 13%, abnormal pH monitoring in 47%. Blown-out myotomy (BOM) described in 30% of POEM patients at 5 years — associated with treatment failure.The landmark RCTs:Boeckxstaens et al., NEJM 2011 Comparison: PD vs LHM (n=201, mean 43 months follow-up) Result: No significant difference. Success rates 86% PD vs 90% LHM at 2 years; 82% vs 84% at 5 years. Established PD and LHM as equivalent in safety and efficacy.Ponds et al., JAMA 2019 Comparison: POEM vs PD (n=126, 2-year primary endpoint) Result: POEM superior — 92% vs 54% at 2 years; 81% vs 40% at 5 years. Reflux esophagitis: 41% POEM vs 7% PD. POEM wins on efficacy; pays a significant GERD price.Werner et al., NEJM 2019 Comparison: POEM vs LHM + Dor fundoplication (n=221, 2-year primary endpoint) Result: Noninferiority met — 83% POEM vs 82% LHM. No significant differences in esophageal function or quality of life. Reflux esophagitis: 44% POEM vs 29% LHM at 2 years; 41% vs 31% at 5 years. POEM and LHM equivalent in efficacy; POEM carries higher reflux burden without fundoplication.Guideline recommendations:ACG: LHM, PD, and POEM are all comparable for Type I and II. POEM preferred for Type III.ASGE: Tailored myotomy (POEM or LHM) preferred for Type III. Patients should be counseled on POEM's higher GERD risk.Board PearlsBoard trap: POEM versus LHM for Type I/II — equivalent efficacy, but POEM carries significantly higher GERD burden because there is no fundoplication.High-yield: Nissen fundoplication is contraindicated in achalasia. Partial wrap (Dor or Toupet) is the rule when peristalsis is impaired.High-yield: Botulinum toxin is not a definitive therapy. If a board option offers it as first-line — it is a distractor.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related